SALT LAKE CITY, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ:MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Sam Raha as Chief Operating Officer (COO), effective December 11, 2023.
Raha adds more than 25 years of general management, commercial, and operations experience, deeply rooted in life sciences and molecular diagnostics, to the team at Myriad Genetics. In his role as COO, he will be responsible for driving the company's lab operations, customer service initiatives, and product development innovations.
"Sam is an accomplished leader who understands how to build teams and drive a patient-centric culture, with a proven ability to define, execute and deliver profitable growth for companies within the diagnostics space," said Paul Diaz, President and CEO, Myriad Genetics. "He will play an integral role in shaping Myriad's long-term growth strategy, while delivering new perspectives and expertise ...